---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-004061"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:27:23.699773+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Israeli court approves Chemomab repurchase of 582,023 ADSs from co-founders

## Summary
- Approved repurchase of up to 582,023 ADSs for approx. $1,213,400 to help co-founders pay tax.
- Tax liability stems from merger deferral that expires March 16, 2023.
- Repurchase at market price to avoid bulk sales that could depress CMMB ADS price.
- Company says cash runway unchanged, expected through end of 2023.

## SEC filing metadata
- accession: 0001178913-22-004061
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004061/0001178913-22-004061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004061/zk2228768.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-004061
- JSON: https://secwatch.observer/filing/0001178913-22-004061.json
- Plain text: https://secwatch.observer/filing/0001178913-22-004061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.